Skip to main content

Advertisement

SpringerLink
Log in

Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV–HCV–coinfected patients under highly active antiretroviral treatment

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

Insulin resistance is associated with highly active antiretroviral therapy in HIV-infected patients, and the risk of developing insulin resistance is increased in hepatitis C virus (HCV)-infected patients. The aim of the present study was to determine whether hepatitis C virus infection constitutes an additional risk factor for insulin resistance or other prothrombotic conditions in HIV–HCV coinfected patients under highly active antiretroviral therapy. One hundred eighteen HIV-infected patients were studied: 50 who had no history of anti-HIV treatment and 68 who were receiving therapy with highly active antiretroviral treatment. The treatment-naive group consisted of 35 HCV-negative subjects and 15 HCV-positive ones. Within the treated group, 50 patients were HCV negative and 18 were HCV positive. For each patient, the lipid profile was determined and the following values measured: glucose, soluble P-selectin (as a marker of platelet activation), soluble thrombomodulin, von Willebrand factor and soluble vascular cell adhesion molecule-1 (as endothelial markers), and insulin resistance. No significant difference (p>0.05) for any variable was found among subjects with or without HCV coinfection in the treatment-naïve group. Among patients under highly active antiretroviral therapy, however, those with HCV coinfection showed higher values (p<0.05) for insulin resistance (homeostasis model assessment value: 2.65 vs. 1.79), glucose (93 vs. 86 mg/dl), endothelial markers (von Willebrand factor, 204 vs. 123%; soluble vascular cell adhesion molecule-1, 650 vs. 482 ng/ml), and platelet activation marker (soluble P-selectin, 78 vs. 51 ng/ml) in parallel with lower CD4+ cells counts (289 vs. 402 cells/mm3) and higher HIV-1 viral loads (305 vs. 50 copies/ml) compared to patients without HCV coinfection. Glucose, soluble P-selectin, and von Willebrand factor were independently related to HCV infection. The presence of HCV coinfection during HIV treatment was closely related to higher values of insulin resistance, to activated platelets, and to endothelial perturbation in parallel with lower CD4+ cell counts and higher HIV-1 viral loads compared to patients without HCV coinfection. On the basis of these results, it may be preferable to treat HCV infection prior to initiating treatment for HIV infection in HIV–HCV–coinfected patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Grunfeld C, Tien P (2003) Difficulties in understanding the metabolic complications of acquired immune deficiency syndrome. Clin Infect Dis 37 (Suppl 2):S43–S46

    Article  PubMed  CAS  Google Scholar 

  2. Powderly WG (2002) Long-term exposure to lifelong therapies. J Acquir Immune Defic Syndr 29 (Suppl 1):S28–S40

    PubMed  Google Scholar 

  3. Carr A (2003) HIV lipodystrophy: risk factors, pathogenesis, diagnosis and management. AIDS 17 (Suppl 1):s141–s148

    Article  PubMed  CAS  Google Scholar 

  4. Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chishol DJ, Cooper DA (1999) Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 353:2093–2099

    Article  PubMed  CAS  Google Scholar 

  5. Mulligan K, Grunfeld C, Tai VW, Algren H, Pang M, Chernoff DN, Lo JC, Schambelan M (2000) Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 23:35–43

    PubMed  CAS  Google Scholar 

  6. Dubé MP, Johnson DL, Currier JS, Leedom JM (1997) Protease inhibitor-associated hyperglycaemia. Lancet 350:713–714

    Article  PubMed  Google Scholar 

  7. Botella JI, Valero MA, Muñoz V, Hurtado A, Varela C (2000) Complete resolution of protease inhibitor induced diabetes mellitus. Clin Endocrinol 52:241–250

    Article  CAS  Google Scholar 

  8. Martinez E, Conget I, Lozano L, Casamitjana R, Gatell JM (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13:805–810

    Article  PubMed  CAS  Google Scholar 

  9. Koster JC, Remedi MS, Qiu H, Nichols CG, Hruz PW (2003) HIV protease inhibitors acutely impair glucose-stimulated insulin release. Diabetes 52:1695–1700

    Article  PubMed  CAS  Google Scholar 

  10. Grinspoon S (2003) Mechanisms and strategies for insulin resistance in acquired immune deficiency syndrome. Clin Infect Dis 37 (Suppl 2):S85–S90

    Article  PubMed  CAS  Google Scholar 

  11. Andersen O, Haugaard SB, Andersen UB, Friis-Møller N, Storgaard H, Vølund A, Nielsen JO, Iversen J, Madsbad S (2003) Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in β-cell function. Metabolism 52:1343–1353

    Article  PubMed  CAS  Google Scholar 

  12. Cines DB, Pollak ES, Buck CA, Loscalzo J, Zimmerman GA, McEver RP, Pober JS, Wick TM, Konkle BA, Schwartz BS, Barnathan ES, McCrae KR, Hug BA, Schmidt AM, Stern DM (1998) Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 91:3527–3561

    PubMed  CAS  Google Scholar 

  13. Blann AD, Seigneur M, Steiner M, Miller IP, McCollum CN (1998) Circulating ICAM-1 and VCAM-1 in peripheral artery disease and hypercholesterolaemia: relationship to the location of atherosclerotic disease, smoking and in the prediction of adverse events. Thromb Haemost 79:1080–1085

    PubMed  CAS  Google Scholar 

  14. Blankenberg S, Rupprecht HJ, Bickel C, Peetz D, Hafner G, Tiret L, Meyer J (2001) Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 104:1336–1342

    Article  PubMed  CAS  Google Scholar 

  15. de Larrañaga GF, Petroni A, Deluchi G, Alonso BS, Benetucci JA (2002) Viral load and disease progression as responsible for endothelial activation and/or injury in HIV-1 infected patients. Blood Coag Fibrinol 14:15–18

    Article  Google Scholar 

  16. Konrad T, Zeuzem S, Toffolo G, Vicini P, Teuber G, Briem D, Lormann J, Lenz T, Herrmann G, Berger A, Cobelli C, Usadel KH (2000) Severity of HCV-induced liver damage alters glucose homeostasis in noncirrhotic patients with chronic HCV infection. Digestion 62:52–59

    Article  PubMed  CAS  Google Scholar 

  17. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL (2000) Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. Ann Intern Med 133:592–599

    PubMed  CAS  Google Scholar 

  18. Mehta SH, Strathdee SA, Thomas DL (2001) Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev 23:302–312

    PubMed  CAS  Google Scholar 

  19. Tedaldi EM, Baker RK, Moorman AC, Alzola CF, Furhrer J, McCabe RE, Wood KC, Holmberg SD, and the HIV Outpatients Study Investigators (2003) Influence of coinfection with hepatitis C virus on morbidity and mortality due to human immunodeficiency virus infection in the era of highly active antiretroviral therapy. Clin Infect Dis 36:363–367

    Article  PubMed  Google Scholar 

  20. Klein MB, Lalonde RG, Suissa S (2003) The impact of hepatitis C virus coinfection on HIV progression before and after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 33:365–372

    PubMed  CAS  Google Scholar 

  21. Pérez-Cano R, Fernández-Gutiérrez C, López-Suárez A, Mira J, Girón-González JA (2002) Factors related to the chronicity and evolution of hepatitis C infection in patients co-infected by the human immunodeficiency virus. Clin Microbiol Infect 8:589–597

    Article  PubMed  Google Scholar 

  22. Sterling RK, Contos MJ, Sanyal AJ, Luketic VA, Stravitz RT, Wilson MS, Mills AS, Shiffman ML (2003) The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr 32:30–37

    PubMed  CAS  Google Scholar 

  23. Howard AA, Klein RS, Schoenbaum EE (2003) Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drugs users. Clin Infect Dis 36:1318–1323

    Article  PubMed  Google Scholar 

  24. Mehta SH, Moore RD, Thomas DL, Chaisson RE, Sulkowski MS (2003) The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons. J Acquir Immune Defic Syndr 33:577–584

    Article  PubMed  CAS  Google Scholar 

  25. Macias J, Pineda JA, Lozano F, Corzo JE, Ramos A, León E, García-García JA, Fernández-Rivera J, Mira JA, Gómez-Mateo J (2003) Impaired recovery of CD4+ cell counts following highly active antiretroviral therapy in drug-naive patients coinfected with human immunodeficiency virus and hepatitis C virus. Eur J Clin Microbiol Infect Dis 22:675–680

    Article  PubMed  CAS  Google Scholar 

  26. Jenny-Avital ER (2003) HCV-coinfection is associated with diabetes and CD4 decline. AIDS Clin Care 15:103

    Article  PubMed  CAS  Google Scholar 

  27. Den Brinker M, With FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van Leeuwen R, Pakker NG, Reiss P, Danner SA, Weverling GJ, Lange JM (2000) Hepatitis B and C co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14:2895–2902

    Article  PubMed  Google Scholar 

  28. Uberti-Foppa C, De Bona A, Morsica G, Galli L, Gallotta G, Boeri E, Lazzarin A (2003) Pretreatment of chronic active hepatitis C in patients coinfected with HIV and hepatitis C virus reduces the hepatotoxicity associated with subsequent antiretroviral therapy. J Acquir Immune Defic Syndr 33:146–152

    Article  PubMed  Google Scholar 

  29. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, Moriya K, Koike K (2004) Hepatitis C virus infection and diabetes: involvement of the virus in the development of insulin resistance. Gastroenterology 126:840–848

    Article  PubMed  CAS  Google Scholar 

  30. Duong M, Petit JM, Piroth L, Grappin M, Buisson M, Chavanet P, Hillon P, Portier H (2001) Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Syndr 27:245–250

    CAS  Google Scholar 

  31. Pober JS (1988) Cytokine-mediated activation of vascular endothelium. Am J Pathol 133:426–433

    PubMed  CAS  Google Scholar 

  32. Blann A, Seigneur M (1997) Soluble markers of endothelial cell function. Clin Hemorheol 17:3–11

    CAS  Google Scholar 

  33. Kaplanski G, Farnarier C, Payan MJ, Bongrand P, Durand JM (1997) Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C. Dig Dis Sci 42:2277–2284

    Article  PubMed  CAS  Google Scholar 

  34. de Larrañaga G, Galich A, Puga L, Alonso B, Benetucci J (2004) Insulin resistance status is an important determinant of PAI-1 levels in HIV infected patients, independently of the lipid profile. J Thromb Haemost 2:532–534

    Article  PubMed  Google Scholar 

  35. Kim SH, Abbasi F, Reaven GM (2004) Impact of degree of obesity on surrogate estimates of insulin resistance. Diabetes Care 27:1998–2002

    Article  PubMed  Google Scholar 

Download references

Acknowledgement

This study was supported by a school grant from MSD Corporation, USA.

Author information

Authors and Affiliations

  1. Hemostasis and Thrombosis Laboratory, Hospital of Infectious Diseases “F.J. Muñiz”, Uspallata 2272, C1282AEN, Buenos Aires, Argentina

    G. F. de Larrañaga, S. D. A. Perés Wingeyer & B. S. Alonso

  2. Retrovirus Laboratory of FUNDAI, Hospital of Infectious Diseases “F.J. Muñiz”, Uspallata 2272, C1282AEN, Buenos Aires, Argentina

    L. M. Puga & J. A. Benetucci

Authors
  1. G. F. de Larrañaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. D. A. Perés Wingeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. M. Puga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. B. S. Alonso
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. A. Benetucci
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. F. de Larrañaga.

Rights and permissions

Reprints and permissions

About this article

Cite this article

de Larrañaga, G.F., Wingeyer, S.D.A.P., Puga, L.M. et al. Relationship between hepatitis C virus (HCV) and insulin resistance, endothelial perturbation, and platelet activation in HIV–HCV–coinfected patients under highly active antiretroviral treatment. Eur J Clin Microbiol Infect Dis 25, 98–103 (2006). https://doi.org/10.1007/s10096-006-0090-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-006-0090-6

Keywords

Search

Navigation